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Objectives of the guidelines
Aim was the update of the guidelines' version of 2009. 5 The primary goal of these guidelines was to assist health care professionals in the choice of the optimal systemic treatment for their psoriasis patients with the specific circumstances of the individual patient.
Target population
These guidelines are targeted at all health care professionals involved in the treatment of patients with psoriasis, primarily dermatologists and general practitioners (GP).
Methods
For the development of these evidence and consensus-based guidelines, the available evidence of the efficacy and safety of the systemic treatments for psoriasis was summarized. Based on the evidence, recommendations were formulated and consented by an expert panel in a structured consensus process.
Groups involved in the guidelines development
The Division of Evidence based Medicine (dEBM) from the Department of Dermatology, Venereology and Allergology, Charit e -Universit€ atsmedizin Berlin, Germany coordinated the guidelines development process including the organization of the guidelines process, development of methodology and the conduction of a systematic review of the literature on the systemic treatment of psoriasis vulgaris. Members of the dEBM participated in or moderated the consensus conference, but were not entitled to vote on recommendations.
Members of the expert group were dermatologists and a rheumatologist. They were officially nominated by the European Dermatology Forum (EDF), the European Association for Dermatology and Venereology (EADV) and the International Psoriasis Council (IPC). The expert group members were selected by virtue of their clinical experience and/or research expertise in the field of psoriasis vulgaris and their previous work on the first version of the European S3-Guidelines on the systemic treatment of psoriasis vulgaris in 2009.
An international patient organization to nominate representatives for patients affected by psoriasis vulgaris could not be identified, and thus patient participation was difficult to realize. Patient representatives from the UK and Italy each participated in the guidelines development process as a part of the expert group. These representatives had the same voting rights as the other members of the expert group and participated in the process of the internal review too. Furthermore one chapter, namely 'Severity assessment/Quality of life -Patients perspective' which is integrated in the main chapter 'introduction to psoriasis vulgaris' was written by the patient representatives. Patient reported outcomes such as DLQI scores were considered as a relevant outcome and studies reporting on these endpoints were included into the systematic literature review. Patients were invited to take part in the external review and to comment the drafted guidelines document.
A steering group of the guidelines project was composed by members of the expert group who have experiences in the field of guidelines development. The steering group was responsible for the selection of interventions, outcomes and relevant patient subgroups in the evidence assessment process.
A full list of the guidelines steering group and expert group members is supplied at the beginning of this document on page 2.
Funding of the guidelines and management of conflicts of interest
The guidelines project has kindly been supported by the EDF. The financial support did not influence the guidelines development. The expert group did not receive financial incentives or reimbursement for the participation in the guidelines development. Assessment and synthesis of the evidence were done independently from industrial interest. Key questions to be answered and outcomes were chosen in accordance to consensus of the members from the steering group. Recommendations on the systemic treatment of psoriasis vulgaris were exclusively based on the consensus of the members from the expert group in the consensus conference, according to the clinical expertise and evidence assessment.
A declaration of potential conflicts of interest (COI) adapted from the International Committee of Medical Journal Editors 6 was required for the participation in the guidelines development. At the beginning of the formalized consensus conference, each member was asked to update his or her declaration. COI were discussed. The expert group did not see any substantial conflicts of interest and there were no further comments or remarks. COI of each person involved in the guidelines development are presented in Appendix 4.1.
preparation of the systematic literature review were performed via electronic mail contacts and decided with the members of the expert group.
Selection of included interventions. The following treatment options were selected as relevant treatments for psoriasis vulgaris and included in the evaluation:
Monotherapies:
Although fumaric acid esters are licensed only in Germany, it is known that they are used in several other European countries as off-label medication (e.g. UK 7 ) for psoriasis vulgaris and they are therefore included in the evidence-based assessment. The biological agent efalizumab 8 lost its marked authorization for psoriasis. Alefacept is licensed in Switzerland and the US only, but is currently not being distributed any more. Both medications were therefore excluded from the guidelines. Furthermore, the expert panel decided to exclude phototherapy due to the high number of studies for which the evidence work up was not feasible during this update (time and costs).
Following combination therapies were selected 1 :
• Included systemic therapy combined with another included systemic therapy
• Included systemic therapy + any topical treatment
Combinations of more than two treatment options were not considered. Studies on combination therapies were included if they compared the combination with the included systemic monotherapy to evaluate the benefit of the combination in comparison to the monotherapy.
The fact that certain treatments were not included does not necessarily imply that it may not be an appropriate treatment for psoriasis vulgaris.
Selection and rating of outcomes. The evaluation of the treatment options was based on efficacy, patient reported as well as safety outcomes. Beside these parameters, other outcomes were selected that seem to be of high importance to the patient. 9, 10 According to the GRADE methodology, expert group members were asked to rate outcomes with respect to their relevance for clinical decisions concerning the choice of a treatment for psoriasis vulgaris on a scale from 1 to 9 with 1 representing irrelevant and 9 representing critical outcomes. Mean values of the ratings from the experts served to rank the importance of the selected outcomes when grading the available evidence. A mean score of 7-9 rated an outcome as critical for a decision, 4-6 rated an outcome as important but not critical for decision making, and a mean score of 1-3 indicated that the respective outcome was of limited importance. 11 Only critical and important outcomes were considered in the evidence assessment. Table 1 shows the selected outcomes and assigned rating of importance.
For reasons of feasibility and to ensure comparability, for the induction therapy the outcomes had to be reported at week 16 after the start of treatment or whatever was closest to that time point, however, not earlier than week 8. 12 For long-term therapy, the results had to be reported for week 24 or whatever was closest thereafter.
To be included into the systematic review, studies had to report at least one of the selected outcomes. Outcomes had to be reported as events per patients in case of dichotomous outcomes (the number of events and the number of patients at the time of assessment had to be reported) or as mean change in case of continuous outcomes (the mean and standard deviation had to be reported). Eligibility criteria with respect to study type and population. Eligible studies for inclusion were initial RCTs (including placebo controlled or head-to-head trials) reporting on participants with a clinical diagnosis of psoriasis vulgaris independent of the publication type. A minimal number of 10 evaluated participants per study arm was required and a minimal treatment duration of 8 weeks. Publication language was not restricted.
Regarding the study population the following criteria were defined:
• Psoriasis vulgaris/plaque type psoriasis • Adults (minimum of 18 years, or as defined in the study, e.g. 'adults') At least 80% of the study participants need to fulfil the above mentioned population criteria.
Literature search: Search for guidelines and systematic
reviews As these guidelines are an update of the previous version, 1,5 there was no systematic search for existing guidelines and systematic reviews on systemic treatments of psoriasis vulgaris. Titles and abstracts of the search were individually checked for eligibility by two independent assessors (AJ, SR). Full texts of potentially relevant studies were similarly checked for eligibility by two independent assessors (AJ, SR). In the case of disagreement during the screening of abstracts and full texts, a third assessor (AN) was involved and the conflict solved by discussion ( Fig. 1 ).
Data extraction
Data collection of the literature search results was done independently by two assessors (AJ, SR), using a standardized data extraction form (Microsoft â Excel worksheet, Table 2 ). All relevant outcome data were then transferred in a Review Manager file. 13 2.3.5 Data analysis Risk ratios with 95% CI for dichotomous data and mean differences with 95% CI for continuous data were calculated for each study comparison.
In case of continuous data with missing standard derivation (SD), SD was calculated from standard error or confidence interval if available. No other SD imputation methods were performed and results from comparisons without any measure of variance were not considered for meta-analysis.
The effect estimates of the individual studies were pooled in meta-analysis using the random effects model (Review Manager 5.2). We included numerous multi-arm studies in our analyses. If multiple comparisons of one study were included into one meta-analysis, we split the shared group into two or three groups with smaller sample size to avoid double-counting of the participants that would create a unitof-analysis error.
Studies with no events in both arms were excluded from the meta-analysis, because they do not provide any information of either the direction or magnitude of the relative treatment effect 3 .
Limited placebo controlled data were available for longterm treatment. Most of the long-term studies 'loose' their placebo group after the induction period. Only three longterm studies were identified that provide placebo controlled data for week 24. To include long-term data from studies without a long-term placebo group, long-term placebo data from the three studies were pooled to calculate the 'placebo response'. Based on the original size of the 'lost' placebo arms, placebo values for long-time studies with lost placebo groups were imputed using the pooled placebo response. Placebo data were available for PASI75, PASI90 and PGA 'clear/ almost clear'. Identified placebo data at week 24 are provided in Table 3 .
The method used to calculate the mean time until onset of action (TOA 25 PASI 75 [w] and TOA 25% mean PASI [w]) is described elsewhere. 9 A drug was assessed to have a slightly faster onset of action than its comparator if the difference of time was > 0.5 weeks; a faster onset of action was described by a difference of > 1 week.
2.3.6
Quality assessment of the evidence The quality of the included studies was assessed by using the Cochrane Risk of bias tool. 3 The available evidence and its quality were summarized 14 GRADE evidence profiles were developed for each available treatment comparison, based on the rated outcomes (see chapters 2.3.1). The quality of the evidence for each key question was categorized into one of four categories, from 'very low' to 'high'. 15 Table 4 summarizes the different quality levels of evidence and the approach used to grade the quality of evidence as suggested by the GRADE working group. 15 The following criteria, as presented by the GRADE working group were applied to decrease or increase the quality ratings for each key question, intervention and outcome:
Limitations to the study quality. The Cochrane risk of bias tool 3 was used to assess limitations to the study quality on a study level. The following domains were assessed: random sequence generation, allocation concealment, incomplete outcome data, selective reporting, blinding of participants and personnel, blinding of outcome assessment and other sources of bias. Overall study quality depended on the limitations of the contributing studies. A downgrading of 1 ('serious limitations') or 2 points ('very serious limitations') was possible. 16 In addition to these criteria quality was downgraded by two points in case of imputed placebo group data.
Inconsistency. Overall quality of evidence was downgraded by 1 point ('important inconsistency'), when the study results were heterogeneous with respect to the direction or the size of the effect. The main criteria for downgrading were: widely varying point estimates across the studies, minimal or no overlap of the confidence intervals (CI), large I² (I² is a statistical test quantifying the variation in the point estimate between the studies). 17 Inconsistency could not be assessed in case of only one contributing study and no downgrading was performed.
Indirectness. When differences between the effect size in the populations recruited for the study participation and the patient subgroup to make a recommendation for were expected (due to significant and important differences in the studied populations to the target population), overall study quality was downgraded by 1 ('some') or 2 points ('major uncertainty about the directness'). 18 Here, study quality was downgraded, when the study inclusion criteria or the patient characteristics at baseline did not match exclusively one of the predefined patient subgroups (e.g. study population consist of patients with mild psoriasis).
Imprecision. The main criterion for determining the precision of the pooled effect size is the width and position of the 95% confidence interval (CI) 19 : the overall study quality was downgraded for imprecision if the CI was very wide, crossed the threshold of minimal important difference (defined as the line of no effect AE 0.25) or if the CI crossed the line of no effect and the threshold of minimal important difference. For continuous outcomes such as the mean reduction in PASI, the minimal important difference was calculated as the line of no effect AE 0.5*SD of the control group.
For outcome data calculated in secondary analysis (i.e. TOA) the quality of evidence was downgraded twice, because no mea- We are very confident that the true effect lies close to that of the estimate of effect.
Moderate (+++)
We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Observational studies* Low Low (++) Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low (+)
We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
*Observational studies were not included in the evidence-based assessment of these Guidelines (see chapter 2.3.1 paragraph 'Eligibility criteria with respect to study type and population').
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Publication bias. When publication bias was expected to influence the size or direction of the effect, study quality was downgraded by 1 point. 20 Due to the low number of contributing trials for each comparison, no formal testing (e.g. visual characterization of funnel plots) could be performed.
Large effect/evidence of dose-response gradient/confounders that would have decreased the effect. Rating up the quality of evidence due to the mentioned reasons is generally recommended only to be applied to results from observational studies or non-randomized trials. 21 As the systematic literature search was restricted to randomized controlled trials, no upgrading of the overall study quality was performed. The quality of the evidence was evaluated by two assessors (AJ, SR) after discussion of each aspect. Comments to justify the ratings are supplied in case of downgrading.
Presentation of the results
For each comparison of interventions, a short text summarizing the available evidence and a GRADE summary of findings table is presented in the guidelines. Data are presented as risk ratios (dichotomous outcomes) 22 or mean differences (continuous outcomes). 23 The summary of finding tables served as the basis for developing the treatment recommendations.
Special considerations and special patient populations
In addition to the recommendation for the general psoriasis patient population, the guideline provides recommendations for special considerations and special patients: The recommendations for subchapters are not based on systematically assessed literature and represent expert opinions. Although topicals and UV are not the focus of the guideline, the group decided on mentioning them for these subpopulation, where they are highly relevant as first line treatments.
Development of recommendations/consensus process
Prior the consensus conference, the draft of the guideline including the results of the systematic literature review was circulated in the expert group. Using the Delphi technique a first voting on the drafts of recommendations on drugs and on therapies in special patient populations was performed and alternative suggestions were collected where required.
During the consensus conference performed on October 9th and 10th in Amsterdam, The Netherlands, the formal consensus methodology of the nominal group technique was used to agree upon the recommendations. 24 All expert group members were entitled to vote on the recommendations. The nominal group technique was moderated by Alexander Nast, MD, certified moderator for the German Association of Scientific Medical Societies (AWMF).
To simplify the identification of consented recommendations, all consented recommendations are highlighted throughout the guidelines document (grey boxes). To avoid ambiguity, a standardized language was used to classify the direction and strength of each recommendation.
Based on the GRADE approach, five strengths of recommendations were differentiated: strong recommendations for or against the use of an intervention, weak recommendations for or against the use of an intervention, and no recommendation. 25 The strength of a recommendation based on the quality of the evidence (high/moderate/low/very low), the balance of expected undesirable and desirable outcomes and consideration of costs as well as of values and preferences. 25, 26 The strength of recommendation was expressed by the wording and symbols (Table 5) .
For each recommendation, the strength of consensus in terms of percentage of agreement was measured and documented. Three levels of consensus were defined and distinguished. A 'strong consensus' defined as an agreement of at least 95% of the members of the expert group was generally aimed at. In cases where only lower values of agreement were achieved, these were defined as 'consensus' (75-94% agreement) or 'weak consensus' (50-74% agreement).
The sections 'Instructions for use' and 'Lab control' of each medication were discussed and consented as a whole within the expert group, at which no strength of recommendation was provided in the guidelines text.
Peer review and piloting
Before publication, the guidelines draft underwent an extensive internal and external review.
Internal review was accomplished at the beginning of the guidelines development to confirm the selection of key questions (kick-off conference), prior to the consensus conference for a preliminary review of the results from the systematic literature review, after the consensus conference to confirm the completed recommendations, and after the external review to confirm changes before publication.
The EDF disseminated the draft to its members for external review. The external review was performed in cooperation with the EADV, UEMS and IPC. In addition, any other interested individual was free to participate in the external review, as the guidelines draft was accessible online for open comments from 27th January 2015 through 23rd February 2015 (using the platform www.crocodoc.com). Each comment was categorized as 'editorial change', 'forwarded to authors for consideration' or 'rejected (including reasoning)'. This document with all responses is available at the dEBM.
As a result of the comments and suggestions of the external review the expert group re-voted on three issues using a modified Delphi technique. These were namely (i) blood count monitoring in therapy with fumaric acid esters, (ii) instruction for use for woman of childbearing age after etanercept therapy and (iii) the definition of 'second line' in the footnote of the treatment recommendation of ustekinumab. For the results of revoting, see final version of guidelines text.
During the phase of external review, the members of the expert panel piloted the drafted guidelines within their own practices and were encouraged to comment on the practicability and results during the second internal review.
European guidelines are intended to be adapted to the national circumstances of each health system.
Implementation, evaluation, updating
European guidelines are intended to be adapted to national or regional circumstances (regulatory approval and availability of treatments, health care provider and insurance systems). Thus, the national medical societies associated to the EDF will be responsible for the adaption and implementation of the guidelines on a national level. The guidelines publication and this methods report will be published online (http://www.euroderm.org/index.php/edf-guidelines). Evaluation strategies with respect to the awareness of the treatment necessity among patients and physicians, the treatment adhesion and treatment success should be pursued at a national level.
Due to the increasing amount of publications, guidelines need to be continually updated to reflect the recent state of evidence. After December 31st, 2019, these guidelines will expire. Should important changes occur in the meantime (such as new available interventions, new important evidence or withdrawal of drug licensing) the information may expire earlier. In these cases, an update issue of the guidelines is needed earlier. The EDF will be responsible to initiate an update. 25, 26 
Strength
Wording Symbols Implications
Strong recommendation for the use of an intervention 'We recommend . . .' ↑↑ We believe that all or almost all informed people would make that choice. Clinicians will have to spend less time on the process of decision making, and may devote that time to overcome barriers to implementation and adherence. In most clinical situations, the recommendation may be adopted as a policy
Weak recommendation for the use of an intervention 'We suggest . . .' ↑ We believe that most informed people would make that choice, but a substantial number would not. Clinicians and health care providers will need to devote more time on the process of shared decision making. Policy makers will have to involve many stakeholders and policy making requires substantial debate
No recommendation with respect to an intervention 'We cannot make a recommendation with respect to . . .'
o At the moment, a recommendation in favour or against an intervention cannot be made due to certain reasons (e.g. no evidence data available, conflicting outcomes, etc.)
Weak recommendation against the use of an intervention 'We suggest not . . .' ↓ We believe that most informed people would make a choice against that intervention, but a substantial number would not.
Strong recommendation against the use of an intervention
'We recommend not . . .' ↓↓ We believe that all or almost all informed people would make a choice against that intervention. This recommendation can be adopted as a policy in most clinical situations 
